Antiplatelet Therapy after Coronary Artery Bypass Grafting: Current Status and Future Perspectives
DOI:
https://doi.org/10.14738/bjhr.1301.19806Keywords:
Aspirin, antiplatelet therapy, clopidogrel, coronary artery bypass grafting, dual antiplatelet therapyAbstract
Antiplatelet therapy is a critical component in managing patients undergoing coronary artery bypass grafting (CABG) to prevent graft occlusion and reduce thrombotic events. Current treatment options primarily include monotherapy with aspirin, dual antiplatelet therapy (DAPT), combining aspirin with a P2Y12 inhibitor, and, in some cases, triple therapy incorporating an anticoagulant. Recent advancements have focused on optimizing treatment regimens to balance the efficacy of antithrombotic protection with the associated risks of bleeding. Personalized treatment approaches, driven by patient-specific factors and genetic profiling, are increasingly recognized as essential for improving patient outcomes. Ongoing research aims to identify biomarkers that can predict patient responses to antiplatelet therapy, enabling more precise and effective treatment strategies. Additionally, novel therapeutic targets and new antiplatelet agents are being investigated to enhance the safety and efficacy of treatment. The results of these studies will shape the future of antiplatelet therapy and contribute to better clinical practices. The integration of genetic and pharmacogenomic data is anticipated to play a significant role in the personalization of antiplatelet therapy, ultimately leading to improved patient care in the context of CABG. This review article provides a comprehensive analysis of the current status and future perspectives of antiplatelet therapy in CABG.
References
Bottardi A, Prado GFA, Lunardi M, Fezzi S, Pesarini G, Tavella D, Scarsini R, Ribichini F. Clinical Updates in Coronary Artery Disease: A Comprehensive Review. J Clin Med.
Bloom JE, Vogrin S, Reid CM, Ajani AE, Clark DJ, Freeman M, Hiew C, Brennan A, Dinh D, Williams-Spence J, Dawson LP, Noaman S, Chew DP, Oqueli E, Cox N, McGiffin D, Marasco S, Skillington P, Royse A, Stub D, Kaye DM, Chan W. Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival. Eur Heart J. 2025;46:72-80.
Salikhanov I, Koechlin L, Gahl B, Zellweger MJ, Haaf P, Müller C, Berdajs D. In-Hospital Graft Occlusion in Post-Coronary Artery Bypass Grafting Patients in the Early Postoperative Period: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13:5514.
Zhu Y, Zhang W, Dimagli A, Han L, Cheng Z, Mei J, Chen X, Wang X, Zhou Y, Xue Q, Hu J, Tang M, Wang R, Song Y, Kang L, Redfors B, Gaudino M, Zhao Q. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. 2024;385:e075707.
Vilahur G, Fuster V. Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis. Eur Heart J. 2025;46:413-423.
Arockiam S, Staniforth B, Kepreotis S, Maznyczka A, Bulluck H. A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. Int J Mol Sci. 2023;24:11132.
Enström P, Martinsson A, Rezk M, Nielsen S, Björklund E, Landenhed-Smith M, Pan E, Jeppsson A. The four-item PRECISE-DAPT score identifies coronary artery bypass grafting patients with increased risk for post-discharge major bleeding. Eur Heart J Cardiovasc Pharmacother. 2024 Aug 20:pvae060.
Ruel M, Chikwe J. Coronary Artery Bypass Grafting: Past and Future. Circulation.
Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M; PANTHER Collaboration. P2Y Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J Am Coll Cardiol. 2023;82:89-105.
Farmer D, Jimenez E. Re-evaluating the Role of CABG in Acute Coronary Syndromes. Curr Cardiol Rep. 2020;22:148.
Siller-Matula JM, Sandner S. Short DAPT for PCI after CABG: ready for prime time. EuroIntervention. 2022;18:e868-e869.
Solo K, Lavi S, Kabali C, Levine GN, Kulik A, John-Baptiste AA, Fremes SE, Martin J, Eikelboom JW, Ruel M, Huitema AA, Choudhury T, Bhatt DL, Tzemos N, Mamas MA, Bagur R. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ. 2019;367:l5476. Scholar Publishing
Chen S, Zhang S, Cai S, Wang H. Impact of frailty on outcomes following coronary artery bypass grafting: a systematic review and meta-analysis. BMC Surg. 2024;24:419.
Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133-48.
Kim JS, Kang Y, Sohn SH, Hwang HY. Comparative effectiveness of clopidogrel versus aspirin as a maintenance monotherapy 1 year after coronary artery bypass grafting. Eur J Cardiothorac Surg. 2023;63:ezad128.
Nei SD, Wamsley KS, Mara KC, Stulak JM, Zieminski JJ. Safety Comparison of Monotherapy Aspirin to Dual Antiplatelet Therapy Following Coronary Artery Bypass Surgery. Clin Appl Thromb Hemost. 2022:10760296221124902.
Hess NR, Sultan I, Wang Y, Thoma F, Kilic A. Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. Am J Cardiol. 2021;148:44-52.
Rocha-Gomes JN, Saraiva FA, Cerqueira RJ, Moreira R, Ferreira AF, Barros AS, Amorim MJ, Pinho P, Lourenço AP, Leite-Moreira AF. Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes. J Cardiovasc Surg (Torino). 2020;61:662-672.
Writing Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:197-215.
Kruse-Jarres R. Acquired bleeding disorders in the elderly. Hematology Am Soc Hematol Educ Program. 2015;2015:231-6.
Alfredsson J, Neely B, Neely ML, Bhatt DL, Goodman SG, Tricoci P, Mahaffey KW, Cornel JH, White HD, Fox KA, Prabhakaran D, Winters KJ, Armstrong PW, Ohman EM, Roe MT; TRILOGY ACS Investigators. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart. 2017;103:1168-1176.
Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B. Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639]. Trials. 2012;13:148.
Comanici M, Bhudia SK, Marczin N, Raja SG. Antiplatelet Resistance in Patients Who Underwent Coronary Artery Bypass Grafting: A Systematic Review and Meta-Analysis. Am J Cardiol. 2023;206:191-199.
Tantry US, Gurbel PA. Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. Curr Pharm Des. 2013;19:3795-815.
Shubbar Q, Alchakee A, Issa KW, Adi AJ, Shorbagi AI, Saber-Ayad M. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Front Pharmacol.
Luo X, Hou M, He S, Yang X, Zhang P, Zhao Y, Xing H. Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis. Front Pharmacol. 2023;13:1021584. Scholar Publishing
Lewis BS. Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue. Eur Heart J Cardiovasc Pharmacother. 2025;11:1-2.
Angiolillo DJ, Galli M, Alexopoulos D, Aradi D, Bhatt DL, Bonello L, Capodanno D, Cavallari LH, Collet JP, Cuisset T, Ferreiro JL, Franchi F, Geisler T, Gibson CM, Gorog DA, Gurbel PA, Jeong YH, Marcucci R, Siller-Matula JM, Mehran R, Neumann FJ, Pereira NL, Rizas KD, Rollini F, So DYF, Stone GW, Storey RF, Tantry US, Berg JT, Trenk D, Valgimigli M, Waksman R, Sibbing D. International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update. JACC Cardiovasc Interv. 2024;17:2639-2663.
Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R, Capodanno D, Valgimigli M, Mehran R, Perrone Filardi P, Cirillo P, Angiolillo DJ; Working Group of Thrombosis of the Italian Society of Cardiology. Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions. JACC Cardiovasc Interv. 2024;17:2197-2215.
Tsigkas G, Vakka A, Apostolos A, Bousoula E, Vythoulkas-Biotis N, Koufou EE, Vasilagkos G, Tsiafoutis I, Hamilos M, Aminian A, Davlouros P. Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review. J Cardiovasc Dev Dis.
Shah J, Liu S, Yu W. Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines. Stroke Vasc Neurol. 2022;7:406-414.
Inshutiyimana S, Ramadan N, Razzak RA, Al Maaz Z, Wojtara M, Uwishema O. Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review. Health Sci Rep. 2024;7:e70139.
Björklund E, Enström P, Nielsen SJ, Tygesen H, Martinsson A, Hansson EC, Lindgren M, Malm CJ, Pivodic A, Jeppsson A. Postdischarge major bleeding, myocardial infarction, and mortality risk after coronary artery bypass grafting. Heart. 2024;110:569-577.
Ruksakulpiwat S, Benjasirisan C, Ding K, Phianhasin L, Thorngthip S, Ajibade AD, Thampakkul J, Zhang AY, Voss JG. Utilizing Social Determinants of Health Model to Understand Barriers to Medication Adherence in Patients with Ischemic Stroke: A Systematic Review. Patient Prefer Adherence. 2023;17:2161-2174.
Johnston N, Weinman J, Ashworth L, Smethurst P, El Khoury J, Moloney C. Systematic reviews: causes of non-adherence to P2Y12 inhibitors in acute coronary syndromes and response to intervention. Open Heart. 2016;3:e000479.
Jourdi G, Godier A, Lordkipanidzé M, Marquis-Gravel G, Gaussem P. Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches. Front Cardiovasc Med. 2022;9:805525.
Sharkiya SH. Quality communication can improve patient-centred health outcomes among older patients: a rapid review. BMC Health Serv Res. 2023;23:886.
Religioni U, Barrios-Rodríguez R, Requena P, Borowska M, Ostrowski J. Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life. Medicina (Kaunas). 2025;61:153.
Kim SK, Park SY, Hwang HR, Moon SH, Park JW. Effectiveness of Mobile Health Intervention in Medication Adherence: a Systematic Review and Meta-Analysis. J Med Syst. 2025;49:13.
Leung DYP, Chung JOK, Chan HYL, Lo RSK, Li K, Lam PT, Ng NHY. Effects of a structured, family-supported, and patient-centred advance care planning on end-of-life decision making among palliative care patients and their family members: protocol of a randomised controlled trial. BMC Palliat Care. 2024;23:257. Scholar Publishing
Santo K, Chow CK, Thiagalingam A, Rogers K, Chalmers J, Redfern J. MEDication reminder APPs to improve medication adherence in Coronary Heart Disease (MedApp-CHD) Study: a randomised controlled trial protocol. BMJ Open. 2017;7:e017540.
Lalani HS, Hwang CS, Kesselheim AS, Rome BN. Strategies to Help Patients Navigate High Prescription Drug Costs. JAMA. 2024;332:1741-1749.
Sim HW, Koh KWL, Poh SC, Chan SP, Marchesseau S, Singh D, Han Y, Ng F, Lim E, Prabath JF, Lee CH, Chen R, Carvalho L, Tan SH, Loh JPY, Tan JWC, Kuwelker K, Amanullah RM, Chin CT, Yip JWL, Lee CY, Gan J, Lo CY, Ho HH, Hausenloy DJ, Tai BC, Richards AM, Chan MY. Remote intensive management to improve antiplatelet adherence in acute myocardial infarction: a secondary analysis of the randomized controlled IMMACULATE trial. J Thromb Thrombolysis.
Galli M, Terracina S, Schiera E, Mancone M, Frati L, Angiolillo DJ, Pulcinelli FM. Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital. J Thromb Thrombolysis. 2025;58:71-83.
Anchidin OI, Rosianu SH, Nemes A, Aldica M, Blendea D, Molnar A, Moldovan H, Pop D. The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic. Medicina (Kaunas).
Bainey KR, Marquis-Gravel G, Belley-Côté E, Turgeon RD, Ackman ML, Babadagli HE, Bewick D, Boivin-Proulx LA, Cantor WJ, Fremes SE, Graham MM, Lordkipanidzé M, Madan M, Mansour S, Mehta SR, Potter BJ, Shavadia J, So DF, Tanguay JF, Welsh RC, Yan AT, Bagai A, Bagur R, Bucci C, Elbarouni B, Geller C, Lavoie A, Lawler P, Liu S, Mancini J, Wong GC. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol. 2024;40:160-181.
Jourdi G, Lordkipanidzé M, Philippe A, Bachelot-Loza C, Gaussem P. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. Int J Mol Sci.
Nappi J. Benefits and limitations of current antiplatelet therapies. Am J Health Syst Pharm. 2008;65(13 Suppl 5):S5-10; quiz S16-8.
Carvalho PEP, Gewehr DM, Nascimento BR, Melo L, Burkhardt G, Rivera A, Braga MAP, Guimarães PO, Mehran R, Windecker S, Valgimigli M, Angiolillo DJ, Bhatt DL, Sandoval Y, Chen SL, Stone GW, Lopes RD. Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. JAMA Cardiol. 2024;9:1094-1105.
Chatters R, Dimairo M, Cooper C, Ditta S, Woodward J, Biggs K, Ogunleye D, Thistlethwaite F, Yap C, Rothman A. Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives. BMJ Open. 2024;14:e075547.
Ingelman-Sundberg M, Pirmohamed M. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. J Intern Med.
Hulot JS, Montalescot G. Do we need a new P2Y12 receptor antagonist? Eur Heart J.
Angiolillo D, Capodanno D, Tamburino C. Update on novel P2Y12 inhibitors: Focus on Prasugrel, Ticagrelor, Cangrelor and Elinogrel. e-J Cardiol Practice. 2020;8:1-10. Scholar Publishing
Mavridis T, Choratta T, Papadopoulou A, Sawafta A, Archontakis-Barakakis P, Laou E, Sakellakis M, Chalkias A. Protease-Activated Receptors (PARs): Biology and Therapeutic Potential in Perioperative Stroke. Transl Stroke Res. 2024 Feb 7. doi: 10.1007/s12975-024-01233-0. Epub ahead of print.
Tantry US, Duhan S, Navarese E, Ramotowski B, Kundan P, Bliden KP, Gurbel P. An update on novel therapies for treating patients with arterial thrombosis. Expert Rev Hematol.
Capodanno D, Angiolillo DJ. Personalised antiplatelet therapies for coronary artery disease: what the future holds. Eur Heart J. 2023;44:3059-3072.
Chen YM, Hsiao TH, Lin CH, Fann YC. Unlocking precision medicine: clinical applications of integrating health records, genetics, and immunology through artificial intelligence. J Biomed Sci. 2025;32:16.
Lopez J, Mark J, Duarte GJ, Shaban M, Sosa F, Mishra R, Jain S, Tran A, Khizar A, Karpel D, Acosta G, Rodriguez-Guerra M. Role of genetic polymorphisms in clopidogrel response variability: a systematic review. Open Heart. 2023;10:e002436.
Woelders ECI, Onuma Y, Ninomiya K, O'Leary N, Damman P, Peeters DAM, Hof AWJV', Valgimigli M, Vranckx P, Windecker S, Serruys PWJC, van Geuns RM. Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy? Open Heart. 2025;12:e003083.
Massmann A, Heukelom JV, Weaver M, Schultz A, Figueroa DM, Stys A, Stys TP, Christensen KD. Evaluation of pharmacogenetic automated clinical decision support for clopidogrel. Pharmacogenomics. 2024;25:391-399.
Galli M, Occhipinti G, Benenati S, Laborante R, Ortega-Paz L, Franchi F, D'Amario D, Nerla R, Castriota F, Frati G, Biondi-Zoccai G, Sciarretta S, Angiolillo DJ. Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2024;10:526-536.
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clin Pharmacokinet. 2015;54:709-35.
Menezes JF, Carvalho MOS, Rocha LC, Dos Santos FM, Adorno EV, de Souza CC, Santiago RP, da Guarda CC, de Oliveira RM, Figueiredo CVB, Carvalho SP, Yahouédéhou SCMA, Fiuza LM, Adanho CSA, Pitanga TN, Lyra IM, Nascimento VML, Noronha-Dutra AA, Goncalves MS. Role of paraoxonase 1 activity and PON1 gene polymorphisms in sickle cell disease. Sci Rep.
Yuan X, Chu Q, Chen K, Wang Y, Zhang L, Zheng Y, Hu S. Multicentre, randomised, doubleblind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOP-CABG trial study. BMJ Open. 2023;13:e070823.
Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77:629-658.
Barron LK, Moon MR. Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns. Cardiovasc Drugs Ther. 2024;38:141-149. Scholar Publishing
Galli M, Laborante R, Ortega-Paz L, Franchi F, Rollini F, D'Amario D, Capodanno D, Tremoli E, Gibson CM, Mehran R, Angiolillo DJ. Factor XI Inhibitors in Early Clinical Trials: A Metaanalysis. Thromb Haemost. 2023;123:576-584.
Krammer TL, Kollars M, Kyrle PA, Hackl M, Eichinger S, Traby L. Plasma levels of plateletenriched microRNAs change during antiplatelet therapy in healthy subjects. Front Pharmacol.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Maria Comanici, Shahzad G. Raja
This work is licensed under a Creative Commons Attribution 4.0 International License.
